Trevena 8K Announces FDA Approval of OLINVYK™ (oliceridine) injection | TRVN 10 Aug 20

Exhibit 99.2

INNOVATING FOR PATIENTS Nasdaq TRVN August 2020

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

5)9)2%?6 E;4)5-)2')( L)%()56,-4 )%1 C-<<51 . B:?<0:A $9.:2-.6; & C12./ E?.,<;2=. #//2,.9 '/:>> A;;71.-?8 ')$, C12./ .0*4 & &.0<4*;79@ #//2,.9 !-<6 A. D185><-/6, !.D. ')$, C12./ !.-2,*4 #//2,.9 B-<<C '459 ')$, C12./ F26*6,2*4 #//2,.9 &:.1<> (. ,:01< ')$, C12./ B<:26.:: #//2,.9 1:9 #. !:?701<, J<. Cha &"a# C-<<51 . B:?<0:A J?751 H. !/H?34 '/:>> B<-?9=>159, !.D. J-61 &. "?99 !5/4-17 &. D:?341<>C A991 !. $45775;=, !.D. !-B591 G:A19, $4.D. B-<.-<-,-995 3 B#A&D #F DI&EC(#&' 'E"I#& !A"AGE!E"(

5)9)2%: I2239%7-9) CNS C314%2< OLINVYK !) !$d!ca*ed !$ ad+"*) f%( * e #a$age#e$* %f ac+*e &a!$ )e,e(e e$%+g *% (e'+!(e a$ !$*(a,e$%+) %&!%!d a$a"ge)!c a$d f%( - %# a"*e($a*!,e *(ea*#e$*) a(e !$ade'+a*e. P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 4 )C )8J C;8@<64? AG<GLy (*A (86;4A<F@ B9 A6G<BAy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

M807-40) E;4)'7)( C%7%0<676 (&)027 "7=.4 A(1 9.,.8;79 :.4.,;2=. *0762:; A?3 2020: ';<-@ 262;2*;276 %1 2021: (78426. -*;* (IC A&D' / -.9:<8-7 /7:>>593 (C#)ID-19) C-**!"-/!1)-, 3)1( I+.%/)!* C-**%'% L-,$-, I# ) (&)734 G-897;.26 :.4.,;2=. *0762:; (5<-78272-9.,.8;79) C-**!"-/!1)-, 3)1( N!1)-,!* I,01)121% -, D/2' A"20% $7C :;<-@ -*;* ("IDA) #;5:50 ?=1 05=:<01< 24%/ C"' "7=.4 '1$ 9.,.8;79 57-<4*;79 24%/ N!1)-,!* I,01)121%0 -& 1H 21: I"D /24260 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. /-1250, /-1734, /-1027, 4A7 /-1045 4E8 <AI8FG<:4G<BA4? CEB7H6GF 4A7 4E8 ABG 4CCEBI87 5L G;8 !DA BE 4AL BG;8E E8:H?4GBEL 4:8A6L. A-D. A6HG8 -8FC<E4GBEL D<FGE8FF .LA7EB@8y $)D $AI8FG<:4G<BA4? )8J DEH:y +BC +EBB9-B9-CBA68CG 5 (&)045C-**!"-/!1)-, 3)1( 05=:<01<= H%!*1( (&)250 G-897;.26 :.4.,;2=. *0762:;A/?>1 853<-591 24%//57&'76%1)2752H 21: C4262,*4 :;<-@ 262;2*;276 (-.4;* 9.,.8;79) # I"),KD ".> ,1.52,*4 .6;2;@A/?>1 ;-59 I# A$$&#)ED 8/07/2020%4 2020: $97-<,; *=*24*+4. (5<-78272-9.,.8;79) $&E-C I"ICA$HA'E 1$HA'E 2$HA'E 3"DA E+$EC(ED CA(A ,'('

OLIN"$K> (30-')5-(-2)) -2.)'7-32: N3: A44539)( 6 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#.

OLIN"$K: D-**)5)27-%7)( P53*-0) *35 A'87) P%-2 (%#'/1$ :D :?5:42E65 :? 25F=ED 7@C E96 >2?286>6?E @7 24FE6 A2:? D6G6C6 6?@F89 E@ C6BF:C6 2? :?EC2G6?@FD @A:@:5 2?2=86D:4 2?5 7@C H9@> 2=E6C?2E:G6 EC62E>6?ED 2C6 :?256BF2E6 E);-7. =;-16 +4161+)4 8:)+<1+-8@=FD / )CA; ?@ 24E:G6 >6E23@=:E6D -? +0-51+)4 -6<1<A D:DE:?4E 7C@> #/ >@CA9:?6 D)<) 16 +7584-@ 8)<1-6<; E=56C=J, @36D6, C6?2= :>A2:C65 & 78171, -..1+)+A "2C5-2?5 D@7E-E:DDF6 DFC86C:6D '-44-+0):)+<-:1B-, ;).-<A I <74-:)*141<A #/ >@CA9:?6 52E2 :?4=F565 :? =236= #)81, )6)4/-;1) 2-5 >:? @?D6E @7 A2:? C6=:67 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. OLINVYK !) $%* c%##e(c!a"". a,a!"ab"e a$d !*) c%$*(%""ed )+b)*a$ce )c ed+"e !) &e$d!$g U.S. DEA ac*!%$. ?

OLIN"$K: B53%( I2(-'%7-32 *35 A'87) P%-2 L(9., (*<;, 4(92,; 67769;<50;@ US ).*&$3"#,& ".",'&2)$ (/20)3", -"1+&3 4.)3 5/,4-&1 45M patients receive IV opioids annually to treat acute pain1 I) 78272-: C $590=(33,+ (5(3.,:0* ,--0*(*@ 38% 45% I) #;5:50= 7,*4 *6.:;1.;2,: C #67 :<9.,90,:: #6;(3 25,, (9;/9673(:;@, *63,*;64@, /,950( 9,7(09, :705, -<:065, C-:,*;0652 I) "'AID' I *,.;*526781.6 17% OLINVYK !) !$d!ca*ed !$ ad+"*) f%( * e #a$age#e$* %f ac+*e &a!$ *% (e'+!(e a$ !$*(a,e$%+) %&!%!d a$a"ge)!c a$d f%( - %# a"*e($a*!,e *(ea*#e$*) a(e !$ade'+a*e. )e,e(e e$%+g P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 8 ).A$DF ABAFG8EB<74? 4AG<-<A9?4@@4GBEL 7EH:F. $(. ($DA. F4?8F 4H7<G 20 7y $1 ).A$DF 4A7 *9<E@8IN. 2 D89<A<G<I8 74G454F8, 4A7 )4G<BA4? 1<G4? .G4G<FG<6F E8CBEG, CDC 20 .

OLIN"$K: D-67-2'7 F531 I" M354,-2) I H<(531354,32) S+, #! #& >1,900 #& #-# ,a$* IV %')("#&! #&c$, ! a* ac+#-! c'%(a)a+') NCE .#+" 2032+ COM (a+!&+1 !:<;4591 HC0<:8:<;4:91 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 2032 6B@CBF<G<BA B9 @4GG8E C4G8AG 8KC<E4G<BA 7B8F ABG <A6?H78 CBG8AG<4? C4G8AG 8KG8AF<BAF. OLIN !K

OLIN"$K: I" O4-3-( E**-'%'< %2( R%4-( O26)7 , Efficac+ achie)ed i" ha%d 'i&&(e & &#f' 'i&&(e !#de & $7.< %1;;=-($" D-24) H):, %1;;=-($" D-48) , Ra$id #"&e': $e%ce$'ib e $ai" %e ief *i'hi" 2-5 !i"('e& ,FA6C:@C A2:? C6=:67 GD. A=2463@ (A<0.01) ,FA6C:@C A2:? C6=:67 GD. A=2463(A<0.02) , OLINVYK efficac+ da'a i" $ee%-%e)ie*ed j#(%"a & The Journal of Pain Research1 (5+ Pain Practice2 &5.) 437*8 (2-5 >:?) & L3 9@FC 5FC2E:@? P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 10 1<F6HF< - 8G 4?. % +4<A -8F. 20 y 2 27P 43. +H5?<F;87 20 (4E. 2 .<A:?4 )& 8G 4?. +4<A +E46G. 20 y 7 5-73 . +H5?<F;87 20 %HA 04.

OLIN"$K: #)00-C,%5%'7)5-=)( S%*)7< I 30)5%&-0-7< Ad. *+ d*-" * ac,$('+ * )(*, d $' 05% (! OLINVYK-,* a, d )a,$ ',+ +,*a,$!$ d b/ da$%/ d(+ (P#a+ 3 )$.(,a% ,*$a%+ )((% d)1 P"2)&-21 4)2( "-6 TEAE (%) !-A?1-);95@5:3 H1-0-/41 D5FF5:1?? C;:?@5<-@5;: HE<;D5-#>A>5@A? &10-@5;: &;9:;81:/1 B-/7 <-5: H;@ 28A?4 #>A>5@A? 31:. P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. *'$)12& +E8F6E<5<A: $A9BE@4G<BA. )BG 4A 478DH4G8 54F<F 9BE 6B@C4E<FBA B9 E4G8F 58GJ88A G;8 *'$)12& GE84G@8AG :EBHC 4A7 G;8 @BEC;<A8 GE84G@8AG :EBHC. 11 Ke/ c'*+-d)#-e)* a**'c#a+ed .#+" IV '(#'#d*: C/-)3).' -C2? C6DF=E :? D:8?:7:42?E 962=E9 C:D<D 2?5 4@>AC@>:D6 C64@G6CJ C S/-./,&.$& -,:8?:7:42?E A2E:6?E D276EJ 4@?46C?, 42? =625 E@ C6DA:C2E@CJ 56AC6DD:@? C O2 2"341"3)/. < 90% -#?56A6?56?E AC65:4E@C @7 62C=J A@DE-@A C6DA:C2E@CJ 4@>A=:42E:@?D P+"$&#. (N = 162) OLIN !K 7 27 ,' (N = 316) M.0/()-& (N = 158) 73 86 96 35 52 70 10 26 52 30 26 30 11 18 25 9 14 14 3 12 17 6 9 19 5 7 13 4 6 10 4 6 6 4 4 8 1 2 10

Da$a in (Real W "ld U#e): C m!le' S%"ge"ie# & Pa$ien$# B96(+ 9(5., 6-:<9.,90,: I 4,+0*(3 796*,+<9,: C4251*< 5&8.*387 ;*6* .3(19)*) A A 32% B 65 @.*9: 46% B!I B 30 C7-579+2-2;2.:: -2*+.;.:, 7+:;9<,;2=. :4..8 *86.*, C#$D, ,19762, I ,*6,.9 8*26 C76,752;*6; 5.-2,*;276:: *6;2.5.;2,:, *6;2+27;2,: A M918.51* .35&8.*38 &3) 4985&8.*38 7*88.3,7 A H7:82;*4 9.,7=.9@ A C92;2,*4 ,*9. A E5.90.6,@ -.8*9;5.6; A A5+<4*;79@ :<902,*4 ,.6;.9: L4; ).7(438.39&8.43 +46 AE7 / 1&(0 4+ *++.(&(= A 2% /79 *-=.9:. .=.6;: A 4% /79 4*,3 7/ .//2,*,@ P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. B8E:8F8 .D 8G 4?. % +4<A -8F84E6;, 20 . /E<4? @B78?87 E84?-JBE?7 HF8 HFH4? C4G<8AG 64E8 J<G; *'$)12& <AFG847 B9 FG4A74E7 $1 BC<B<7. .88 !DA 7E49G :H<74A68 9BE $A7HFGEL D<FGE<5HG<A: .6<8AG<9<6 4A7 (87<64? +H5?<64G<BAF BA 0A4CCEBI87 )8J 0F8F. 12 105/-8 C->05;@4;>-/5/ B->5-@>5/ ?A>31>E E91>31:/E !1A>;8;35/ (>;8;35/ #8-?@5/ ?A>31>E G1:1>-8 ?A>31>E C;8;>1/@-8 ?A>31>E GE:1/;8;35/ ">@4;<105/ 050100150200250 !A9.1> ;2 <-@51:@? 11 18 18 33 39 44 60 84 115 115 231 N = 768

OLIN"$K: E%6) 3* D36-2+ %2( A(1-2-675%7-32 3 =0(3: ;6 (336> -69 -3,?0)3, +6:, (+1<:;4,5; ;(0369,+ ;6 7(;0,5; 5,,+: B74=; D7;16/: 1 5/ )6, 2 5/ =1)4: M#?:E:2= 1.5 >8 5@D6 M,:?8=6 5@D6D @G6C 3 >8 92G6 ?@E 366? 6G2=F2E65 "CA D7;16/: 30 5/ =1)4 M M M #?:E:2= 1.5 >8 5@D6 0.35 >8 / 0.5 >8 56>2?5 5@D6D H:E9 6->:?FE6 =@4<-@FE 0.75 >8 DFAA=6>6?E2= 5@D6D 2E 1 9@FC 2?5 9@FC=J 2D ?66565 For PCA use only )5-8? ->1 588A?@>-@5B1 ;:8E C !LI &(K 1 5/ D 5798016-5 5/ C 27 5/ +<5<4);1=-,)14@ ,7:-4151; P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. OLINVYK !) $%* c%##e(c!a"". a,a!"ab"e a$d !*) c%$*(%""ed )+b)*a$ce )c ed+"e !) &e$d!$g U.S. DEA ac*!%$. 13 +CA +4G<8AG-CBAGEB??87 AA4?:8F<4 3 56*7*38&8.437: 1 50I5:2604.--7:. =2*4 2 50I25 (150I54):2604.--7:. =2*4 30 50I305 (150I54):2604.-8;-<:. =2*4 F79 I) *-5262:;9*;276 764@ "7 9./920.9*;276 I 9.,76:;2;<;276

Customer Engagement Strategy 14

C3145),)26-9) D%7% A9%-0%&0) %7 L%82', &033 :<7769; -<;<9, *644,9*0(30A(;065 (5+ /6:70;(3 -694<3(9@ <7;(2, Hea$+" Ca)e P)ac+#+#'&e)* (HCP*) M M M '6H 496>:42= 6?E:EJ 2DE, 67764E:G6 #/ @A:@:5 A2:? C6=:67 C=:?:42= 52E2 :? 4@>A=6I A2E:6?ED / E2C86E65 DFC86C:6D H'*(#+a$ F')%,$a)/ C'%%#++ee* M )F3=:D965 9625-E@-9625 EC:2=D GD. #/ >@CA9:?6 M )F3=:D965 962=E9 64@?@>:4 / 4@DE @77D6E 52E2* P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. OLINVYK !) $%* c%##e(c!a"". a,a!"ab"e a$d !*) c%$*(%""ed )+b)*a$ce )c ed+"e !) &e$d!$g U.S. DEA ac*!%$. 15 KC86G87 GB 58 CH5?<F;87 4G G<@8 B9 ?4HA6;

R3&867 S)7 3* P))5-R)9-):)( P8&0-'%7-326 C6479,/,5:0=, 6=,9=0,> 6-OLIN%'K +,=,3674,5; 796.9(4 "0);-1 I "0);-2 ,)<) 15 59'1.(&8.437 ;-+76,):A )6)4A;-; 7 59'1.(&8.437 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c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a! (a( *e P& c #g &e'ea&ch, Cha&!e' R *e& A''$c a(e', A%& ! 2020. 2) ,A&e (he "%&$*e"e#(' # &e'% &a($&+ 'afe(+ e*e#(' a#d Gl ($!e&ab ! (+ c! # ca!!+ "ea# #gf)!?-Ba'ed $# OLlNVYK Ph3 c! # ca! (& a! da(a. 1? K1C E90;:59> (@=. I) 8:<;4591) $4-<8-/5=> (9=50) $4C=5/5-9 (9=50) &.:829*;79@ '*/.;@ E=.6;: *6-GI (74.9*+242;@ 72% 76% 41 23 14 13 2

H364-7%0 P,%51%'< C326-()5%7-326 ".% 1&%4$& $/232 ../ ../ ../ D1..-9-6;1);-, )+<;-8)16 897.14-$8,826 05 /6:70;(3 *6:;: 7,9 7(;0,5; -69 5(<:,( I =640;05.1 $).-;@ 16 +7584-? 8);1-6;: H-),-;7-0-), 8--9-9-=1->-, +4161+)4 -=1,-6+-3 $28,000 7,9 *90;0*(3 9,:709(;69@ ,=,5; I :,8<,3(,2 ../ ../ C758-4416/ 0-)4;0 -+76751+ 57,-4 I5*9,(:,+ /6:70;(3 3,5.;/ 6-:;(@: 87 "%%)3)/.", +(@:2 F795<4)9@ :;)3-074,-9 .--,*)+3 :<8879;: B$100I,)@4 *78E74, "(, % +4<A +4??<4G<I8 C4E8 +;4E@, 20 y 74G4 54F87 BA 5 FHE:<64? CEB687HE8 64G8:BE<8F <A6?H7<A: C4E7<BG;BE46<6 I I4F6H?4E, "8A8E4? I CB?BE86G4?, *5 I "LA, *EG;BC87<6, 4A7 0EB?B:<6. 2 *I8E7L> !%, +'B. *A8, 20 . 3 /;8F8 CH5?<64G<BAF J<?? 58 HF87 <A 4 @4AA8E 6BAF<FG8AG J<G; !DA(A F86G<BAF4 4A7 G;8 !DA "H<74A68 G;8E8HA78E. 4 B4F87 BA 74<?L 7BF<A: <A A/# )A QE84? JBE?7R BC8A ?458? F498GL FGH7L 4A7 2020 C-A CE<6<A: FGH7L. /;8 CE<68 9BE *'$)12& ;4F ABG 588A 8FG45?<F;87. 18 I-01/5& $,).)$", /43$/-&2 OLIN !K

%5+)7)( A''3827 L%82', I50;0(3 -6*<:: *6473,? 7(;0,5;: 05 3 2,@ :<9.0*(3 (9,(: >12 75*(.&18.*7 &(6477 7*88.3,7 >5,800 -475.8&17 .3 8-* #! 8550 (/20)3",2 8500 ASC2 C@>>F?:EJ %2C86 C68:@?2= DJDE6>D "@DA:E2= @FEA2E:6?E A>3F=2E@CJ DFC8:42= 46?E6CD 84 20&$)",3)&2 A?6DE96D:@=@8J (CE9@A65:4 C@=@C64E2= !J?64@=@8:4 1 A.CF 4@5H?4GBEL FHE:<64? 68AG8EF 30-40 +<:;75-9-.)+16/ 974-: M &65:42= ,4:6?46 %:2:D@?D M "@DA:E2= A44@F?E &2?286CD I6+4<,-: =19;<)4 HC" -6/)/-5-6; M-,1+)4 E,<+);176 897/9)5: Physician specialties Inpatient & hospital outpatient

L%82', -1)0-2) P3(5505. <5+,9>(@ -69 (5 ,--0*0,5; (5+ ,--,*;0=, *644,9*0(3 3(<5*/ 1Q 2021 4Q 2020 La,&c" D,736@4,5; 6-*<:;64,9--(*05. ;,(4: A4' 7 C DEA Sc"ed,$#&! C "97,<+; )=)14)*4-16 ;9),-+0)66-4 A(()'-a$ C M(5<-(*;<905. 3 =0(3 79,:,5;(;065: P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. OLINVYK !) $%* c%##e(c!a"". a,a!"ab"e a$d !*) c%$*(%""ed )+b)*a$ce )c ed+"e !) &e$d!$g U.S. DEA ac*!%$. 20

OLIN"$K A44539%0 S75%7)+< A003:6 *35 G53:7, 61<1)4 +7:-.7+=; (9!) M M M 8C@25 :?5:42E:@? & 5@D:?8 / 25>:? #/ @A:@:5 677:424J & 72DE @?D6E C@>A=6I A2E:6?ED: 6=56C=J, @36D6, C6?2= DFC8:42= AC@465FC6D ")<1-6< & ":7+-,=:-#1;3 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 21 .BHE68 D89<A<G<I8 #84?G;64E8y A@8E<64A #BFC<G4? AFFB6<4G<BA. AFFH@8F M 00 I 74L CE<68 9BE B?<68E<7<A8 $8-+1)4<A %):/-<; E@8)6,-, ):-); 7. .7+=; (28!) M %6G6C286 C6DA:C2E@CJ 2?5 !# D276EJ GD. #/ >@CA9:?6 E@ 6IA2?5 M C@8?:E:G6 7F?4E:@? & 255:E:@?2= "EC(' L15! 52JD @7 E96C2AJ (:?:E:2= 4@C6 7@4FD) $1.58+ 2&60*8 45546893.8=* C45! 8)<1-6<; EB;-9010 -<1-= :2 2:/?= (28!) I9In5>5i-ti7a/l: l<a1u2n:/ch?= f(o9c!u)s

TRV027 NCE 'a%ge'i"g 'he AT1 %ece$'#% i" COVID-19 22

M807--O5+%2 D%1%+) F531 C3532%9-586 E30405(;065 6-ACE2 796;,05 3,(+: ;6 *90;0*(3 /69465(3 04)(3(5*,: C7976)=19<: *16,: ;7 )6, -41516);-: ACE21 C L-),: ;7 )++<5<4);176 7. )6/17;-6:16 II: - A+<;-4<6/ 162<9@ )6, )*6795)4 *477, +47;: - C)6 4-), ;7 A#D$ I 8<4576)9@ -5*741:5 I :;973-SARS-C. -2 C 66% - 94% 579;)41;@ 9);-.79 C!&ID-19 9-4);-, A#D$2* ACE2 C B1I3 7. 07:81;)41A-, C!&ID-19 8);1-6;: ,-=-478 +47;;16/ +75841+);176:3 23 A-D. A6HG8 -8FC<E4GBEL D<FGE8FF .LA7EB@8. &H54 & 8G 4?., )4G (87, 2005. 2 "<5FBA +" 8G 4?, (87 % AHFG, 2020. $A C4G<8AGF E8DH<E<A: I8AG<?4G<BA. 3 &?B> !A 8G 4?, /;EB@5 -8F, 2020.

R"027: N): MOA *35 CO"ID-19 M,*/(50:4 ;(9.,;,+ ;6 04796=, 3<5. -<5*;065 (5+ 79,=,5; ()5694(3 *36;;05. %#&027 A6027;.6:26 II A(1 9.,.8;79 C.44 :<9/*,. C.44 26;.9279 G 8:7<-16 F-)::-;<16 %#&027 1; <0-764A ;-4-+<1>-A%1 :-+-8<7: )/761;< $).-<A I <74-:)*141<A -;<)*41;0-, 16 C700 8)<1-6<; 24 L93, 6*5&.6 A38.-.3+1&22&846= L93, )&2&,* A'3462&1 '144) (1487

R"027 CO"ID-19 S78(< - I14)5-%0 C300)+) L32(32 I5=,:;0.(;, ,--,*; 6-#!%027 65 )366+ *36;;05., 3<5. -<5*;065, (5+ 6;/,9 *3050*(3 6<;*64,: C #)6,751A-,, ,7<*4--*416,, 84)+-*7-+76;9744-, 8977.-7.-+76+-8; :;<,@ C = B60 (30 8-9 )95) C!&ID-19 8);1-6;: -"@DA:E2=:K65, ?@?-G6?E:=2E65 -N18 J62CD @=5 C I& 16.<:176 7. 84)+-*7 79 %#&027 .79 7 ,)@: (12 5/I09) P1)-"17 &.%0/).3: #-,<+;176 7. )*6795)4 +47;;16/ )::7+1);-, >1;0 C!&ID-19* I6-2,*;79 7/ (&)027D: .//.,; 76 1.*4;1 7<;,75.: *::7,2*;.->2;1 26,9.*:.-579;*42;@ 26 C#)ID-19 25 +E<@4EL 8A7CB<AG D-7<@8E ?8I8?F. ;GGCF II6?<A<64?GE<4?F.:BII6G2IF;BJIE86BE7I)C/044 0.

M807-40) E;4)'7)( C%7%0<676 -78272-9.,.8;79) A?3 2020: ';<-@ 262;2*;276 A&D' / -.9:<8-7 /7:>>593 C-**!"-/!1)-, 3)1( :.4.,;2=. *0762:; (&)734 G-897;.26 :.4.,;2=. *0762:; (5<-78272-9.,.8;79) C-**!"-/!1)-, 3)1( N!1)-,!* I,01)121% -, D/2' A"20% $7C :;<-@ -*;* ("IDA) #;5:50 ?=1 05=:<01< 24%/ C"' C-**!"-/!1)-, 3)1( "7=.4 '1$ 9.,.8;79 57-<4*;79 24%/ 1H 21: I"D /24260 H%!*1( P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. /-1250, /-1734, /-1027, 4A7 /-1045 4E8 <AI8FG<:4G<BA4? CEB7H6GF 4A7 4E8 ABG 4CCEBI87 5L G;8 !DA BE 4AL BG;8E E8:H?4GBEL 4:8A6L. A-D. A6HG8 -8FC<E4GBEL D<FGE8FF .LA7EB@8y $)D $AI8FG<:4G<BA4? )8J DEH:y +BC +EBB9-B9-CBA68CG 26 (&)045 05=:<01<= N!1)-,!* I,01)121%0 -& A/?>1 ;-59I# A$$&#)ED 8/07/2020 %4 2020: $97-<,; *=*24*+4. (&)027 "7=.4 A(1 9.,.8;79(C#)ID 19)# I+.%/)!* C-**%'% L-,$-,%1 2021: (78426. -*;* (IC ) (&)250 G-897;.26 :.4.,;2=. *0762:;A/?>1 853<-591 24%//57&'76%1)2752H 21: C4262,*4 :;<-@ 262;2*;276 (-.4;* 9.,.8;79) (5< ".> ,1.52,*4 .6;2;@ # I"),KD $&E-C I"ICA$HA'E 1$HA'E 2$HA'E 3"DA E+$EC(ED CA(A ,'('

R"250: N): MOA *35 A'87) 5)%71)27 3* M-+5%-2) D,3;( 9,*,7;69: $5;(77,+ 76;,5;0(3 05 CN" :7(*, M0.9(05, 9,79,:,5;: ( 3(9., 4(92,; 67769;<50;@; ;6;(3 40.9(05, +9<. 4(92,; = B$3.5B D-4<) :-+-8<7:; 0)>-=619=-,1;<:1*=<176 <0:7=/07=< <0-*:)16 Every year in the US1: C 20-30% 7. 51/9)16-:<..-9-9: ,7 67; 9-:876, ;7 I +)667; ;74-9);-;0-5)93-;-4-),16/ ;918;)6 ,9</ +4):: 650M 51/:)16-; <:-)<-, -)+0 A-): 1.2M E# >1;1<; ,=-<7 51/:)16-; C A8897?. 50% 7. 51/9)16-<9: )4:7 :<..-9 .975 )6?1-;@2 D4G4 9EB@ D86<F<BA -8FBHE68F, +;4E@46BE @<:E4<A8 @4E>8G ?4A7F64C8 4A7 9BE864FG 20 . 2 (BI8A 8G 4?., % )8HEB? )8HEBFHE: +FL6;<4GEL, 20 . $6BAF @478 5L !E88C<> 9EB@ JJJ.9?4G<6BA.6B@ 2? P3(@ 04769;(5; 963, 05 9,.<3(;065 6-7(05, 466+, (5+ (5?0,;@

R"250: #)00-30)5%7)( -2 P,1 H)%07,< "30827))5 PK S78(< "<)*<;(5,6<: +6:,: <7 ;6 30 4. :;<+0,+; 56 "AE: 6):,9=,+ $16/4-,7;-80):5)+7316-<1+; 7. %#&250 /1>-6 *A $C 162-+<176 C &,33 ;63,9(;,+, >0;/ 56 "AE: (*96:: )96(+ 9(5., 6-+6:,: C P9,+0*;()3, PK: +6:,-796769;065(3 ),;>,,5 0.1 4. ;6 30 4. "C C H(3--30-, *65:0:;,5; (*96:: (33 +6:,: C N6 EEG -05+05.: 6):,9=,+ 05 (5@ :<)1,*; .C FH56HG4A8BHF. !BFF?8E (% 8G 4?., C). DEH:F, AH: 2020y34( 53-5.

R"734: M%-27)2%2') ,)5%4< *35 O4-3-( !6) D-635()5 ",3,*;0=, (.650:4 (; D 9,*,7;69: P6;,5;0(3 -69 04796=,+ ;63,9()030;@ O.'/).' $/,,"#/1"3)/. 6)3( N"3)/.", I.23)343& /. D14' A#42& (NIDA) M '@?4=:?:42= 6G:56?46 @7 :>AC@G65 E@=6C23:=:EJ H:E9 -+/734 >2.5M 7,673, 05 $.". :<--,9 -964 67060+ <:, +0:69+,91 M '#DA DEF5J 56>@?DEC2E65 C65F465 5CF8-D66<:?8 3692G:@C :? 2?:>2= >@56= @7 C6=2AD62 M CFCC6?E E96C2A:6D ?@E H6== E@=6C2E65, 42? 9:?56C A2E:6?E 2596C6?46 NIDA-,&ded ()'' -' -c'&ce(+ (a+#e&+ *+,d/ #&#+#a+ed 2 C8AG8E 9BE B8;4I<BE4? #84?G; .G4G<FG<6F 4A7 ,H4?<GL. 2 )$DA 74G4 BA 9<?8.

TRV045: Ne'$-Gene"a$ion 51P Mod%la$o" fo" CN5 Di#o"de"# N,> MOA (; "1P, >0;/6<; (::6*0(;,+ 3@47/67,50( *:*67*7 P&.3 *75437* 100 ** * 80 M ,1) C646AE@CD :? E96 C', A=2J F?:BF6 C@=6 :? >@5F=2E:?8 ?6FC@EC2?D>:DD:@? / >6>3C2?6 6I4:E23:=:EJ 60 40 d yperalgesia 20 M #? 2?:>2=D, -+/045 C6G6CD65 A24=:E2I6=-:?5F465 9JA6C2=86D:2 H:E9@FE :>>F?6-DFAAC6DD:?8 24E:G:EJ 0 F)-'.+), .% 0.03 m g/kg po TR 045 1.0 m g/kg sc - - :?8@=:>@5 C65F465 =J>A9@4JE6D 3J 78% -+/045 925 ?@ 67764E @? =J>A9@4JE6D A:4.)7 L=25-45*3.& 6 5 4 3 2 1 0 ** Vehicle M '@?-@A:@:5 &(A H:E9 3C@25 A@E6?E:2= 7@C C', :?5:42E:@?D - - C9C@?:4 A2:?, C#)', 5:236E:4 ?6FC@A2E9J EA:=6ADJ, 24FE6 / 49C@?:4 A2:? 6G2=F2E:@?D F?56CH2J F)-'.+), .% 0.03 m g/kg po TR 045 3.7 m g/kg sc C$+) @BHF8 @B78? +46?<G4K8? @:I>:, <.C. BA D4LF , 3, 5, 7. #LC8E4?:8F<4 @84FHE87 4F % ABA-E8FCBAF8 GB 0.4 : 1BA !E8L 9<?4@8AG IF. 54F8?<A8, G8FG87 30S 49G8E 7BF<A: BA D4L 3. 'L@C;B6LG8F @84FHE87 49G8E 3 74LF B9 7BF<A:. D4G4 4E8 @84A O F.8.@. A 5-7 @<68I:EBHC. C<0.05 BE C<0.0 IF. 6BAGEB? 30 P *$)# *a% L/&)#(c/, + (103 c %%+ I μL) % W$,# N('-R +)('+ ,( Pa$' S,$&-%-+ alone N. 0&%3$2).-%&1/)2& 3.75 %.1)-' (B?. -.;B1) taxel-induce Pacli h

5)9)2%: I2239%7-9) CNS C314%2< OLINVYK !) !$d!ca*ed !$ ad+"*) f%( * e #a$age#e$* %f ac+*e &a!$ )e,e(e e$%+g *% (e'+!(e a$ !$*(a,e$%+) %&!%!d a$a"ge)!c a$d f%( - %# a"*e($a*!,e *(ea*#e$*) a(e !$ade'+a*e. P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 31 )C )8J C;8@<64? AG<GLy (*A (86;4A<F@ B9 A6G<BAy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

APPENDIX 32

R3&867 C0-2-'%0 D)9)0341)27 P53+5%1 OLINVYK *+, #! #& > 1,900 #& #-# ,a$* Phase 1 Phase 2 Phase 3 M N4 )47&,* &)/9782*387 7@C 6=56C=J / C6?2==J :>A2:C65 '@ <?@H? 24E:G6 >6E23@=:E6D 4 -*&)-84--*&) 86.&17 :7. I$ 2465-.3*: M M M M #/ @A:@:5 677:424J +2A:5 @?D6E @7 24E:@? 06==-492C24E6C:K65 C6DA:C2E@CJ D276EJ / !# E@=6C23:=:EJ %@H C2E6D @7 G@>:E:?8 2?5 C6D4F6 2?E:6>6E:4 FD6 M L&6,* 7&+*8= 789)=: M +62=-H@C=5 FD6 :? 4@>A=6I A2E:6?ED 2?5 E2C86E DFC86C:6D P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 33 FH5=86GF 8KCBF87 GB *'$)12& <A +; 3 y C4G<8AGF GE84G87 J<G; *'$)12& <A +;2 4A7 +;3 ,535

P5-1%5< E**-'%'< E2(43-27 A',-)9)( -2 :3 P-937%0 S78(-)6 OLIN%'K (*/0,=,+ I% 67060+ ,--0*(*@ # < 0.0001 p == 0.0004 80% p < 0.0001 70% 80% 70% p == 0.029 60% 60% 50% 50% 40% 40% 30% 30% 20% 10% 20% 10% 0% 0% #8-/1.; 0. 1 93 0. 35 93 0. 5 93 #8-/1.; 0. 1 93 0. 35 93 0. 5 93 -*)#%/)$),% -*)#%/)$),% P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 34 *'$)12& E8:<@8AF .5 @: ?B47<A: 5B?HF, J<G; 0. , 0.35, BE 0.5 @: 4I4<?45?8 BA 78@4A7 8I8EL @<AHG8F. D<FC?4L87 C-I4?H8F 4E8 9BE *'$)12& IF. C?4685B J<G; #B6;58E: @H?G<C?<6<GL 47=HFG@8AG. 1<F6HF< - 8G 4?. % +4<A -8F. 20 y 2 27P 43. +H5?<F;87 20(4E. .<A:?4 )& 8G 4?. +4<A +E46G. 20 y7 5-73 . +H5?<F;87 20%HA 04. A-"+'&1)$ 0&1/.-%&0 0"2& A-"+'&1)$ 0&1/.-%&0 0"2& H):, <1;;=-$7.< <1;;=-

OLIN"$K: I" O4-3-( E**-'%'< -2 2 P,%6) 3 RC 6 $<=,A 1 (!:<078-,1+ D H):, %1;;=-) 3 $CA 9.025.6: :;<-2.-(0.1, 0.35, 0.5 50) =:. 84*,.+7 *44 -7:.: $<0.01 =:. 84*,.+7 10 9 8 7 6 5 4 3 2 1 0 P/%')&2 (1=? ) 0LIN#$K 0 10+ (1=?6) 0LIN#$K 0 350+ (1=? ) 0LIN#$K 0 50+ (1=? ) 0 4 8 12 16 20 24 28 32 36 40 44 48 10 9 8 7 6 5 4 3 2 1 0 $<=,A 2 ("4);<1+ $=:/-:A D $7.< %1;;=-) 3 $CA 9.025.6: :;<-2.-(0.1, 0.35, 0.5 50) =:. 84*,.+7 0.35 I 0.5 50 -7:.: $<0.02 =:. 84*,.+7 P/%')&2 (1=81) 0LIN#$K 0 10+ (1=??) 0LIN#$K 0 350+ (1=80) 0LIN#$K 0 50+ (1=80) 0 4 8 12 16 20 24 T)-& ((/412) 35 P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. A5&1"'& NRS P"). S$/1& OLINVYK O-,c(& 0.1 &" 0.35 &" 0.5 &" P%ac b( % C203/)6)( 86% 0% 8?% ?4% % 0/C L0E 11% 3% 5% 22% % !)5'7) M)(5 31% 21% 18% 4 % OLINVYK O-,c(& 0.1 &" 0.35 &" 0.5 &" P%ac b( % C203/)6)( 83% 8?% 84% 60% % 0/C L0E % 4% 5% 34% % !)5'7) M)(5 41% 20% 1?% ??%

N3 A''8180%7-32 D)64-7) R)4)%7)( D36-2+ M<3;0-D6:, ; # ";<+@ K*= 6*79187 x 2 %( 3#g e,e(. 2 () 40093 (<;?5@5B1 A ": -//?8?7->5:9 >4<:?34 24 4<= !.*6 %(,I <105: *; 22 7/ 24 8726;: A ": /->13:<5/-7 %(/ :?>751<= C >60 5: >500 5: *+:74<;. A *177 >:71<->10, 9: 'AE=* 92% 9.*,1.-5*? -*24@ -7:. *",) )**)'6 21" 342/21+%6-21 %6 626%/ '707/%6-8) (%-/: (25)5 >2? 0+ ,%5 126 &))1 567(-)( -1 % 6,2427+," 567(: "26%/ '707/%6-8) (%-/: (25)5 )9'))(-1+ 2? 0+ 3)4 (%: 0%: -1'4)%5) 6,) 4-5. *24"' -16)48%/ 342/21+%6-21 ",)4)*24), 6,) '707/%6-8) 626%/ (%-/: (25) 2* 0LIN#$K 5,27/( 126 )9'))( 2? 0+ P"ea)e )ee I#&%(*a$* Safe*. I$f%(#a*!%$ !$c"+d!$g BOXED WARNING a* * e e$d %f &(e)e$*a*!%$. F+"" P(e)c(!b!$g I$f%(#a*!%$ a* ---.OLINVYK.c%#. 3 FH5=86GF ABG 7BF87 7H8 GB ?46> B9 I8ABHF 4668FF7<F6BAG<AH4G<BA 7H8 GB 4 ABA-F8E<BHF 47I8EF8 8I8AG (4FL@CGB@4G<6 ABA-FHFG4<A87 I8AGE<6H?4E G46;L64E7<4 J<G; 6BA9BHA7<A: ;LCB>4?8@<4 4A7 AB @84A<A:9H? ,/ CEB?BA:4G<BA 7HE<A: 7BF<A:, FH5=86G 6B@C?8G87 7BF<A: 5HG ABG 8I4?H45?8 7H8 GB 8DH<C@8AG @4?9HA6G<BA 36 O*)#%/)$),%M-4)&*-4!#), 20 15 10 M%!, 66QT#I 5 (+0%#) [90% CI 0 -5 ?9>11<= -10 -15 0246810 12 14 16 18 20 22 24 T)+% ((-2/0) (2793 9-D)/;:@>;8) " = 68 41-7>4C @:7

ln$e"ac$i n Be$&een $he AT1 Rece!$ " and ACE2 in COVlD-19 D6>59,.<3(;065 6-ACE2 )@ *6965(=09<: 05+09,*;3@ 79646;,: (*;0=(;065 6-;/, A#1 9,*,7;69 C C6965(=09<: )05+: ;6 (5+ +6>59,.<3(;,: (5.06;,5:05 *65=,9;05. ,5A@4, 2 (ACE2)1 C D,*9,(:, 05 ACE2 ,3,=(;,: (5.06;,5:05 II 3,=,3: - A6/17;-6:16 II )+;1=);-: A%1 9-+-8;79 - 7 *9-)3,7>6 7. )6/17;-6:16 II 16;7 A6/(1-7) o '@C>2==J, A?8(1-7) 24ED 2D 2 O-2CC6DE:?-3:2D65 =:82?5 2E E96 A-1 C646AE@C2 o )C@E64E:G6 E96C2A6FE:4 36?67:ED :? E96 =F?8D3 3? &H54 & 8G 4?., )4G (87, 2005. 2 /8<K8<E4 'B 8G 4?., .6< -8C, 20 7. 3 .4AGBF -A. 8G 4?., +;LF<B? -8I, 20 . SARS-C-V-2 ACE2 V)/!* %,1/5 !,$ ACE2 $-3,/%'2*!1)-,

Del$a Rece $o" Agoni#$# Ha&e Uni!%e Benefi$# P6;,5;0(3 <;030;@ -69 ( =(90,;@ 6-CN" 05+0*(;065: T)#(+a&* I D#+a&* C #(9.,;: :,96;6505 9,*,7;69: 4,+0(;, =(:*<3(9 ,?*0;()030;@ ((::6*0(;,+ C% 90:2)1 C M0.9(05,-:7,*0-0* ;9,(;4,5; CGRP* C #(9.,;: CG!P 9,*,7;69: 9,.<3(;, 5,<965(3 :;9<*;<9,: 05=63=,+ 05 7(05 :0.5(305.2 C M0.9(05,-:7,*0-0* ;9,(;4,5; De$+a )ece(+') a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

IMPORTANT SAFETY INFORMATION 3

L/2/9'9/438 4, "8+ B+)':8+ 4, 9.+ 7/808 4, '**/)9/43, '(:8+, '3* 2/8:8+ </9. 45/4/*8, +;+3 '9 7+)422+3*+* *48+8, 7+8+7;+ OLIN#$K ,47 :8+ /3 5'9/+398 ,47 <.42 '19+73'9/;+ 97+'92+39 459/438 %+.-., 343-45/4/* '3'1-+8/)8 47 45/4/* )42(/3'9/43 574*:)98&: G H';+ 349 (++3 941+7'9+*, 47 '7+ 349 +=5+)9+* 94 (+ 941+7'9+* G H';+ 349 574;/*+* '*+6:'9+ '3'1-+8/', 47 '7+ 349 +=5+)9+* 94 574;/*+ '*+6:'9+ '3'1-+8/'. !.+ ):2:1'9/;+ 949'1 *'/1> *48+ 8.4:1* 349 +=)++* 27 2-, '8 949'1 *'/1> *48+8 -7+'9+7 9.'3 27 2-2'> /3)7+'8+ 9.+ 7/80 ,47 Q!) /39+7;'1 574143-'9/43. CONTRAINDICATIONS OLIN#$K /8 )4397'/3*/)'9+* /3 5'9/+398 </9.: • /-3/,/)'39 7+85/7'947> *+57+88/43 • A):9+ 47 8+;+7+ (743)./'1 '89.2' /3 '3 :3243/947+* 8+99/3-47 /3 9.+ '(8+3)+ 4, 7+8:8)/9'9/;+ +6:/52+39 • K34<3 47 8:85+)9+* -'8974/39+89/3'1 4(897:)9/43, /3)1:*/3-5'7'1>9/) /1+:8 • K34<3 .>5+78+38/9/;/9> 94 41/)+7/*/3+ (+.-., '3'5.>1'=/8) WARNINGS AND PRECAUTIONS • OLIN#$K )439'/38 41/)+7/*/3+, ' ).+*:1+ [controlled substance schedule pending] )4397411+* 8:(89'3)+, 9.'9 +=548+8 :8+78 94 9.+ 7/808 4, '**/)9/43, '(:8+, '3* 2/8:8+. A19.4:-. 9.+ 7/80 4, '**/)9/43 /3 '3> /3*/;/*:'1 /8 :3034<3, /9 )'3 4)):7 /3 5'9/+398 '557457/'9+1> 57+8)7/(+* OLIN#$K. A88+88 7/80, )4:38+1, '3* 243/947 '11 5'9/+398 7+)+/;/3-45/4/*8. • +7/4:8, 1/,+-9.7+'9+3/3-7+85/7'947> *+57+88/43 .'8 (++3 7+5479+* </9. 9.+ :8+ 4, 45/4/*8, +;+3 <.+3 :8+* '8 7+)422+3*+*, +85+)/'11> /3 5'9/+398 </9. ).743/) 5:1243'7> */8+'8+, 47 /3 +1*+71>, )').+)9/) '3* *+(/1/9'9+* 5'9/+398. !.+ 7/80 /8 -7+'9+89 *:7/3-/3/9/'9/43 4, OLIN#$K 9.+7'5>, ,4114</3-' *48+ /3)7+'8+, 47 <.+3 :8+* </9. 49.+7 *7:-8 9.'9 *+57+88 7+85/7'9/43. P745+7 *48/3-4, OLIN#$K /8 +88+39/'1, +85+)/'11> <.+3 )43;+79/3-5'9/+398 ,742 '349.+7 45/4/* 574*:)9 94 ';4/* 4;+7*48+. M'3'-+2+39 4, 7+85/7'947> *+57+88/43 2'> /3)1:*+ )148+ 4(8+7;'9/43, 8:55479/;+ 2+'8:7+8, '3* :8+ 4, 45/4/* '39'-43/898, *+5+3*/3-43 9.+ 5'9/+39A8 )1/3/)'1 89'9:8. • O5/4/*8 )'3 )':8+ 81++5-7+1'9+* (7+'9./3-*/847*+78 /3)1:*/3-)+397'1 81++5 '53+' (C A) '3* 81++5-7+1'9+* .>54=+2/' </9. 7/80 /3)7+'8/3-/3 ' *48+-*+5+3*+39 ,'8./43. I3 5'9/+398 <.4 57+8+39 </9. C A, )438/*+7 *+)7+'8/3-9.+ *48+ 4, 45/4/* :8/3-(+89 57')9/)+8 ,47 45/4/* 9'5+7. INDICATIONS AND USAGE OLIN#$K /8 ' 3+< ).+2/)'1 +39/9> /3*/)'9+* /3 '*:198 ,47 9.+ 2'3'-+2+39 4, '):9+ 5'/3 8+;+7+ +34:-. 94 7+6:/7+ '3 /397';+34:8 45/4/* '3'1-+8/) '3* ,47 <.42 '19+73'9/;+ 97+'92+398 '7+ /3'*+6:'9+. 40 WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; ,# RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS A##("2(-,, A!31$, ,# M(131$ OLINVYK $6.-1$1 . 2($,21 ,# -2'$0 31$01 2-2'$ 0(1)1 -% -.(-(# ##("2(-,, !31$, ,# +(131$, 5'("' " , *$ # 2--4$0#-1$ ,# #$ 2'. A11$11 $ "' . 2($,291 0(1) !$%-0$ .0$1"0(!(,& OLINVYK, ,# +-,(2-0 ** . 2($,21 0$&3* 0*7 %-0 2'$ #$4$*-.+$,2 -% !$' 4(-01 -0 "-,#(2(-,1. L(%$-T'0$ 2$,(,& R$1.(0 2-07 D$.0$11(-, S$0(-31, *(%$-2'0$ 2$,(,&, -0 % 2 * 0$1.(0 2-07 #$.0$11(-, + 7 -""30 5(2' 31$ -% OLINVYK. M-,(2-0 %-0 0$1.(0 2-07 #$.0$11(-,, $1.$"( **7 #30(,& (,(2( 2(-, -% OLINVYK -0 %-**-5(,& #-1$ (,"0$ 1$. N$-, 2 * O.(-(# W(2'#0 5 * S7,#0-+$ P0-*-,&$# 31$ -% OLINVYK #30(,& .0$&, ,"7 " , 0$13*2 (, ,$-, 2 * -.(-(# 5(2'#0 5 * 17,#0-+$, 5'("' + 7 !$ *(%$-2'0$ 2$,(,& (% ,-2 0$"-&,(8$# ,# 20$ 2$#, ,# 0$/3(0$1 + , &$+$,2 ""-0#(,& 2-.0-2-"-*1 #$4$*-.$# !7 ,$-, 2-*-&7 $6.$021. I% -.(-(# 31$ (1 0$/3(0$# %-0 .0-*-,&$# .$0(-# (, .0$&, ,2 5-+ ,, #4(1$ 2'$ . 2($,2 -% 2'$ 0(1) -% ,$-, 2 * -.(-(# 5(2'#0 5 * 17,#0-+$ ,# $,130$ 2' 2 ..0-.0( 2$ 20$ 2+$,2 5(** !$ 4 (* !*$. R(1) F0-+ C-,"-+(2 ,2 U1$ W(2' B$,8-#( 8$.(,$1 -0 O2'$0 CNS D$.0$11 ,21 C-,"-+(2 ,2 31$ -% -.(-(#1 5(2' !$,8-#( 8$.(,$1 -0 -2'$0 CNS #$.0$11 ,21, (,"*3#(,& *"-'-*, + 7 0$13*2 (, .0-%-3,# 1$# 2(-,, 0$1.(0 2-07 #$.0$11(-,, "-+ , ,# #$ 2'. R$1$04$ "-,"-+(2 ,2 .0$1"0(!(,& %-0 31$ (, . 2($,21 %-0 5'-+ *2$0, 2(4$ 20$ 2+$,2 -.2(-,1 0$ (, #$/3 2$; *(+(2 #-1 &$1 ,# #30 2(-,1 2-2'$ +(,(+3+ 0$/3(0$#; ,# %-**-5 . 2($,21 %-0 1(&,1 ,# 17+.2-+1 -% 0$1.(0 2-07 #$.0$11(-, ,# 1$# 2(-,.

WARNINGS AND PRECAUTIONS • P74143-+* :8+ 4, 45/4/*8 *:7/3-57+-3'3)> )'3 7+8:19 /3 </9.*7'<'1 /3 9.+ 3+43'9+ 9.'9 2'> (+ 1/,+-9.7+'9+3/3-. O(8+7;+ 3+<(4738 ,47 8/-38 4, 3+43'9'1 45/4/* </9.*7'<'1 8>3*742+ '3* 2'3'-+ '))47*/3-1>. A*;/8+ 57+-3'39 <42+3 :8/3-OLIN#$K ,47 ' 574143-+* 5+7/4* 4, 9.+ 7/80 4, 3+43'9'1 45/4/* </9.*7'<'1 8>3*742+ '3* +38:7+ 9.'9 '557457/'9+ 97+'92+39 </11 (+ ';'/1'(1+. • P74,4:3* 8+*'9/43, 7+85/7'947> *+57+88/43, )42', '3* *+'9. 2'> 7+8:19 ,742 9.+ )43)42/9'39 :8+ 4, OLIN#$K </9. (+3?4*/'?+5/3+8 47 49.+7 CN *+57+88'398 (+.-., 343-(+3?4*/'?+5/3+ 8+*'9/;+8/.>5349/)8, '3=/41>9/)8, 97'36:/1/?+78, 2:8)1+ 7+1'='398, -+3+7'1 '3+89.+9/)8, '39/58>).49/)8, 49.+7 45/4/*8, 47 '1)4.41). B+)':8+ 4, 9.+8+ 7/808, 7+8+7;+ )43)42/9'39 57+8)7/(/3-4, 9.+8+ *7:-8 ,47 :8+ /3 5'9/+398 ,47 <.42 '19+73'9/;+ 97+'92+39 459/438 '7+ /3'*+6:'9+, 57+8)7/(+ 9.+ 14<+89 +,,+)9/;+ *48+, '3* 2/3/2/?+ 9.+ *:7'9/43. • OLIN#$K <'8 8.4<3 94 .';+ 2/1* Q!) /39+7;'1 574143-'9/43 /3 9.474:-. Q! 89:*/+8 <.+7+ 5'9/+398 <+7+ *48+* :5 94 27 2-. !49'1 ):2:1'9/;+ *'/1> *48+8 +=)++*/3-27 2-5+7 *'> <+7+ 349 89:*/+* '3* 2'> /3)7+'8+ 9.+ 7/80 ,47 Q!) /39+7;'1 574143-'9/43. !.+7+,47+, 9.+ ):2:1'9/;+ 949'1 *'/1> *48+ 4, OLIN#$K 8.4:1* 349 +=)++* 27 2-. • I3)7+'8+* 51'82' )43)+397'9/438 4, OLIN#$K 2'> 4)):7 /3 5'9/+398 </9. *+)7+'8+* C>94).742+ P450 (C$P) 2D6 ,:3)9/43 47 3472'1 2+9'(41/?+78 9'0/3-24*+7'9+ 47 89743-C$P2D6 /3./(/9478; '184 /3 5'9/+398 9'0/3-' 24*+7'9+ 47 89743-C$P3A4 /3./(/947, /3 5'9/+398 </9. *+)7+'8+* C$P2D6 ,:3)9/43 <.4 '7+ '184 7+)+/;/3-' 24*+7'9+ 47 89743-C$P3A4 /3./(/947, 47 </9. */8)439/3:'9/43 4, ' C$P3A4 /3*:)+7. !.+8+ 5'9/+398 2'> 7+6:/7+ 1+88 ,7+6:+39 *48/3-'3* 8.4:1* (+ )148+1> 243/947+* ,47 7+85/7'947> *+57+88/43 '3* 8+*'9/43 '9 ,7+6:+39 /39+7;'18. C43)42/9'39 :8+ 4, OLIN#$K </9. C$P3A4 /3*:)+78 47 */8)439/3:'9/43 4, ' 24*+7'9+ 47 89743-C$P3A4 /3./(/947 )'3 14<+7 9.+ +=5+)9+* )43)+397'9/43, <./). 2'> *+)7+'8+ +,,/)')>, '3* 2'> 7+6:/7+ 8:551+2+39'1 *48+8. • C'8+8 4, '*7+3'1 /38:,,/)/+3)> .';+ (++3 7+5479+* </9. 45/4/* :8+ (:8:'11> -7+'9+7 9.'3 43+ 2439.). P7+8+39'9/43 '3* 8>259428 2'> (+ 34385+)/,/) '3* /3)1:*+ 3':8+', ;42/9/3-, '347+=/', ,'9/-:+, <+'03+88, */??/3+88, '3* 14< (144* 57+88:7+. I, )43,/72+*, 97+'9 </9. 5.>8/414-/) 7+51')+2+39 *48+8 4, )479/)489+74/*8 '3* <+'3 5'9/+39 ,742 9.+ 45/4/*. • OLIN#$K 2'> )':8+ 8+;+7+ .>549+38/43, /3)1:*/3-479.489'9/) .>549+38/43 '3* 8>3)45+ /3 '2(:1'947> 5'9/+398. • !.+7+ /8 /3)7+'8+* 7/80 /3 5'9/+398 <.48+ '(/1/9> 94 2'/39'/3 (144* 57+88:7+ .'8 '17+'*> (++3 )425742/8+* (> ' 7+*:)+* (144* ;41:2+ 47 )43):77+39 '*2/3/897'9/43 4, )+79'/3 CN *+57+88'39 *7:-8 (+.-., 5.+349./'?/3+8 47 -+3+7'1 '3+89.+9/)8). M43/947 9.+8+ 5'9/+398 ,47 8/-38 4, .>549+38/43. I3 5'9/+398 </9. • A8 </9. '11 45/4/*8, OLIN#$K 2'> )':8+ 85'82 4, 9.+ 85./3)9+7 4, O**/, '3* 2'> )':8+ /3)7+'8+8 /3 8+7:2 '2>1'8+. M43/947 5'9/+398 </9. (/1/'7> 97')9 */8+'8+, /3)1:*/3-'):9+ 5'3)7+'9/9/8, ,47 <478+3/3-8>259428. • !.+7+ /8 /3)7+'8+* 7/80 /3 5'9/+398 <.48+ '(/1/9> 94 2'/39'/3 (144* 57+88:7+ .'8 '17+'*> (++3 )425742/8+* (> ' 7+*:)+* (144* ;41:2+ 47 )43):77+39 '*2/3/897'9/43 4, )+79'/3 CN *+57+88'39 *7:-8 (+.-., 5.+349./'?/3+8 47 -+3+7'1 '3+89.+9/)8). M43/947 9.+8+ 5'9/+398 ,47 8/-38 4, .>549+38/43. I3 5'9/+398 </9. )/7):1'947> 8.4)0, ';4/* 9.+ :8+ 4, OLIN#$K '8 /9 2'> )':8+ ;'84*/1'9/43 9.'9 )'3 ,:79.+7 7+*:)+ )'7*/') 4:95:9 '3* (144* 57+88:7+. • A;4/* 9.+ :8+ 4, OLIN#$K /3 5'9/+398 </9. /25'/7+* )438)/4:83+88 47 )42'. OLIN#$K 8.4:1* (+ :8+* </9. )':9/43 /3 5'9/+398 <.4 2'> (+ 8:8)+59/(1+ 94 9.+ /397')7'3/'1 +,,+)98 4, CO2 7+9+39/43, 8:). '8 9.48+ </9. +;/*+3)+ 4, /3)7+'8+* /397')7'3/'1 57+88:7+ 47 (7'/3 9:2478, '8 ' 7+*:)9/43 /3 7+85/7'947> *7/;+ '3* 9.+ 7+8:19'39 CO2 7+9+39/43 )'3 ,:79.+7 /3)7+'8+ /397')7'3/'1 57+88:7+. M43/947 8:). 5'9/+398 ,47 8/-38 4, 8+*'9/43 '3* 7+85/7'947> *+57+88/43, 5'79/):1'71> <.+3 /3/9/'9/3-9.+7'5>. • A8 </9. '11 45/4/*8, OLIN#$K 2'> )':8+ 85'82 4, 9.+ 85./3)9+7 4, O**/, '3* 2'> )':8+ /3)7+'8+8 /3 8+7:2 '2>1'8+. M43/947 5'9/+398 </9. (/1/'7> 97')9 */8+'8+, /3)1:*/3-'):9+ 5'3)7+'9/9/8, ,47 <478+3/3-8>259428. • OLIN#$K 2'> /3)7+'8+ 9.+ ,7+6:+3)> 4, 8+/?:7+8 /3 5'9/+398 </9. 8+/?:7+ */847*+78 '3* 2'> /3)7+'8+ 9.+ 7/80 4, 8+/?:7+8 /3 ;:13+7'(1+ 5'9/+398. M43/947 5'9/+398 </9. ' ./8947> 4, 8+/?:7+ */847*+78 ,47 <478+3+* 8+/?:7+ )439741. • D4 349 '(7:591> */8)439/3:+ OLIN#$K /3 ' 5'9/+39 5.>8/)'11> *+5+3*+39 43 45/4/*8. G7'*:'11> 9'5+7 9.+ *48'-+ 94 ';4/* ' </9.*7'<'1 8>3*742+ '3* 7+9:73 4, 5'/3. A;4/* 9.+ :8+ 4, 2/=+* '-43/89/'39'-43/89 (+.-., 5+39'?4)/3+, 3'1(:5./3+, '3* (:9475.'341) 47 5'79/'1 '-43/89 (+.-., (:57+3475./3+) '3'1-+8/)8 /3 5'9/+398 <.4 '7+ 7+)+/;/3-OLIN#$K, '8 9.+> 2'> 7+*:)+ 9.+ '3'1-+8/) +,,+)9 '3*/47 57+)/5/9'9+ </9.*7'<'1 8>259428. • OLIN#$K 2'> /25'/7 9.+ 2+39'1 47 5.>8/)'1 '(/1/9/+8 3++*+* 94 5+7,472 549+39/'11> .'?'7*4:8 ')9/;/9/+8 8:). '8 *7/;/3-' )'7 47 45+7'9/3-2')./3+7>. • A19.4:-. 8+1,-'*2/3/897'9/43 4, 45/4/*8 (> 5'9/+39-)4397411+* '3'1-+8/' (PCA) 2'> '114< +'). 5'9/+39 94 /3*/;/*:'11> 9/97'9+ 94 '3 '))+59'(1+ 1+;+1 4, '3'1-+8/', PCA '*2/3/897'9/43 .'8 7+8:19+* /3 '*;+78+ 4:9)42+8 '3* +5/84*+8 4, 7+85/7'947> *+57+88/43. H+'19. )'7+ 574;/*+78 '3* ,'2/1> 2+2(+78 243/947/3-5'9/+398 7+)+/;/3-PCA '3'1-+8/' 8.4:1* (+ /3897:)9+* /3 9.+ 3++* ,47 '557457/'9+ 243/947/3-,47 +=)+88/;+ 8+*'9/43, 7+85/7'947> *+57+88/43, 47 49.+7 '*;+78+ +,,+)98 4, 45/4/* 2+*/)'9/438. )/7):1'947> 8.4)0, ';4/* 9.+ :8+ 4, OLIN#$K '8 /9 2'> )':8+ ;'84*/1'9/43 9.'9 )'3 ,:79.+7 7+*:)+ )'7*/') 4:95:9 '3* (144* 57+88:7+. ADVERSE REACTIONS A*;+78+ 7+')9/438 '7+ *+8)7/(+* /3 -7+'9+7 *+9'/1 /3 9.+ P7+8)7/(/3-I3,472'9/43. !.+ 2489 )42243 (/3)/*+3)+ @10%) '*;+78+ 7+')9/438 /3 P.'8+ 3 )4397411+* )1/3/)'1 97/'18 <+7+ 3':8+', ;42/9/3-, */??/3+88, .+'*').+, )4389/5'9/43, 57:7/9:8, '3* .>54=/'. • A;4/* 9.+ :8+ 4, OLIN#$K /3 5'9/+398 </9. /25'/7+* )438)/4:83+88 47 )42'. OLIN#$K 8.4:1* (+ :8+* </9. )':9/43 /3 5'9/+398 <.4 2'> (+ 8:8)+59/(1+ 94 9.+ /397')7'3/'1 +,,+)98 4, CO2 7+9+39/43, 8:). '8 9.48+ </9. +;/*+3)+ 4, /3)7+'8+* /397')7'3/'1 57+88:7+ 47 (7'/3 9:2478, '8 ' 7+*:)9/43 /3 7+85/7'947> *7/;+ '3* 9.+ 7+8:19'39 CO2 7+9+39/43 )'3 ,:79.+7 /3)7+'8+ /397')7'3/'1 57+88:7+. M43/947 8:). 5'9/+398 ,47 8/-38 4, 8+*'9/43 '3* 7+85/7'947> *+57+88/43, 5'79/):1'71> <.+3 /3/9/'9/3-9.+7'5>. 41

Trevena (TRVN) 8-KTrevena Announces FDA Approval of OLINVYK™ (oliceridine) injection